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S-nitrosophytochelatins (SNOPCs) are novel analogues of S-nitrosoglutathione (GSNO) with the advan-
tage of carrying varying ratios of S-nitrosothiol (SNO) moieties per molecule. Our aim was to investigate
the in vivo pharmacological potency and biodistribution of these new GSNO analogues after intravenous
(i.v.) and intranasal (i.n.) administration in mice. SNOPCs with either two or six SNO groups and GSNO
were synthesized and characterized for purity. Compounds were administered i.v. or i.n. at 1 mmol NO/kg
body weight to CD-1 mice. Blood pressure was measured and biodistribution studies of total nitrate and
nitrite species (NOx) and phytochelatins were performed after i.v. administration. At equivalent doses of
NO, it was observed that SNOPC-6 generated a rapid and signiﬁcantly greater reduction in blood pressure
(~60% reduction compared to saline) whereas GSNO and SNOPC-2 only achieved a 30e35% decrease. The
reduction in blood pressure was transient and recovered to baseline levels within ~2 min for all com-
pounds. NOx species were transiently elevated (over 5 min) in the plasma, lung, heart and liver. Inter-
estingly, a size-dependent phytochelatin accumulation was observed in several tissues including the
heart, lungs, kidney, brain and liver. Biodistribution proﬁles of NOx were also obtained after i.n.
administration, showing signiﬁcant lung retention of NOx over 15 min with minor systemic increases
observed from 5 to 15 min. In summary, this study has revealed interesting in vivo pharmacological
properties of SNOPCs, with regard to their dramatic hypotensive effects and differing biodistribution
patterns following two different routes of administration.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Nitric oxide (NO) is an extremely versatile signalling molecule
with an extraordinarily diverse array of physiological functions.
Disruption to endogenous NO synthesis pathways is a common
underlying factor in a variety of pathological conditions, impor-
tantly endothelial dysfunction [1,2]. Reduced vascular levels of NO
production are responsible for a variety of cardiovascular disorders
contributing towards elevated blood pressure, vascular remodel-
ling, and thrombotic events [2]. Exogenous administration of NO
via NO-donor molecules has been explored as an attractive thera-
peutic strategy to treat not only cardiovascular disorders [3,4],
underpinned by endothelial dysfunction, but also a variety of other
pathological conditions, including cancer, infection, osteoporosis,).
r Inc. This is an open access articleand wound healing [5e8].
The key to successful therapeutic use of NO-donors is achieving
targeted NO release and a therapeutically suitable pharmacokinetic
proﬁle [9]. Due to the nature of NO as a small, extremely labile and
reactive molecule, this objective has proven very challenging to
achieve. Interest in the development of appropriate NO delivery
systems has increased rapidly across a diverse ﬁeld of applications
[9]. S-nitrosothiols represent a class of NO donors where most have
been previously synthesized as S-mono-nitrosothiols based on two
different thiol moieties, either penicillamine or cysteine. However,
the current trend is the development of di- or poly-S-nitrosothiols
in order to increase the payload of compounds releasing NO, thus
limiting the drug concentration [10,11]. Poly S-nitrosothiols that
have been synthesized include S,S0-dinitrosobucillamine
(BUC(NO)2), which combines in its structure two S-mono-nitro-
sothiols, S-nitroso-N-acetylpenicillamine and S-nitroso-N-ace-
tylcysteine [10]. S-nitroso-b-cyclodextrins; a compound that
combines photochemically and thermally induced NO release withunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and 6-multi-S-nitroso-b-cyclodextrins (SNO-bCDs) were charac-
terized in terms of their SNO content [12]. Poly-S-nitroso albumin
has been developed as a safe and potent multifunctional antitumor
agent [13].This study focuses on the in vivo activity and pharma-
cokinetic proﬁles of a new class of oligopeptide-based NO delivery
systems known as S-nitroso phytochelatins (SNOPCs; Fig. 1).
Phytochelatins (PCs) are cysteine-rich oligopeptides produced
in plants in response to heavy metals, especially Cd2þ, contami-
nation found in soil [14]. Their physiological function is to sequester
reactive heavymetals via chelationwith their cysteine thiol groups,
thereby playing a protective role in detoxiﬁcation. In this way, they
are analogous to metallothioneins in mammals. Structurally, PCs
are similar to glutathione (GSH), with a primary sequence of (g-
Glu-Cys) n eGly where usually n ¼ 2e5, but may reach up to 11 in
higher varieties of plant species and microorganisms [14,15].
Recent studies have also shown that endogenous NO can react with
PCs in plant tissues to produce endogenous mono S-nitrosylated
PCs [16]. Interestingly, in vivomono-S-nitrosylation of PCs occurs in
a site speciﬁc manner, selectively on the single cysteine thiol
nearest the N-terminal group. It is thought that this speciﬁc S-
nitrosylation pattern plays an important role in cell signalling, but
to date, little information on the exact nature of such pathways
exists [16e18].
SNOPCs may also be utilized as oligopeptide-based NO delivery
systems [8,19]. Under in vitro conditions, full S-nitrosylationmay be
achieved, creating an NO delivery system that carries multiple
moieties of S-nitrosothiol groups (SNO). Using isolated rat aortic
rings, we have previously shown that SNOPCs carrying two-, four or
six moieties of SNO (SNOPC-2, -4 or -6) are able to elicit a strong
vasodilatory response, equivalent to GSNO at equal molar concen-
trations of SNO, and more potent than GSNO at equal molar con-
centrations of compound. However, we observed that SNOPCs are
prone to a more rapid physicochemical degradation compared to
GSNO and this reduced their biological activity in protracted in vitro
experiments [19].
As SNOPCs were observed to be excellent transnitrosating
agents under in vitro conditions [19,20], we were interested in
examining their in vivo pharmacological activity andFig. 1. Schematic structures of (A) GSNO, (B) SNOPC-2 and (C) SNOPC-6.biodistribution proﬁles after intravenous (i.v.) injection. Further,
due to a potential therapeutic beneﬁt of inhaled NO donor com-
pounds in diseases such as pulmonary hypertension [21,22], the
pharmacokinetics and biodistribution of SNOPCs and GSNO was
investigated after intranasal (i.n.) administration. Thus, the aim of
this study was to evaluate the pharmacological activity of the
SNOPCs as NO delivery systems after i.v. administration and char-
acterize the pharmacokinetic proﬁle of these compounds (both the
NO component as well as the oligopeptides carriers) after i.v. and
i.n. administration.
2. Materials and methods
2.1. Materials
Phytochelatins PC-2 (Mol. wt. ¼ 540.6 Da) and PC-6 (Mol.
wt. ¼ 1468.6 Da) were obtained from ANASPEC (Mountain View,
CA, USA). Fluorescent-labelled glutathione, PC-2 and PC-6 (conju-
gated with 7-methoxy coumarin) were obtained from PEPCEUT-
ICALS Limited (Leicestershire, UK). Coomassie Plus (Bradford)
Protein Assay reagent was purchased from Thermo Fisher Scientiﬁc
(Rockford, USA). All other analytical grade chemicals and reagents
were purchased from SigmaeAldrich (Dorset, UK). Mice (male CD-
1, 8 weeks old) were purchased from Charles River UK Ltd.
2.2. Synthesis and characterization of GSNO and SNOPCs
Stock solutions of GSNO, SNOPC-2 and -6 were prepared as
previously described [20]; an equal volume of acidiﬁed nitrite so-
lution (NaNO2/0.9 MHCl) was added to the appropriate glutathione
or phytochelatin solution (in 0.9% saline) using equimolar ratios of
thiol groups:NaNO2 under conditions where light was excluded.
The ﬁnal pH of the solutions was maintained at 7.4 using 4 mol/L
NaOH in 0.1 mol/L Tris buffer. S-nitrosation efﬁciency (%) was
quantiﬁed and calculated using UV/Vis absorbance at l ¼ 334 nm
(Cary Varian-300; UK). S-nitrosation efﬁciencies were 100, 95 and
89% for GSNO, SNOPC-2 and SNOPC-6, respectively. *GSNO and
*SNOPCs (*peptides labelled with 7-methoxycoumarin) were S-
nitrosated according to the same method and it was determined
that the label did not interfere with S-nitrosation efﬁciency
(*GSNO: 98%, *SNOPC-2: 94%, and *SNOPC-6: 88%). All solutions
were stored under light exclusion on ice and were administered
within 30 min of preparation.
2.3. In vivo studies
All animal experiments were performed under UK Home Ofﬁce
approval according to the Animals Scientiﬁc Procedures Act, 1986.
Studies were designed and conducted in accord with the ARRIVE
guidelines. Experiments were conducted at approximately the
same time of day to account for diurnal variation. Drug adminis-
tration was randomized and unblinded, but data was analyzed by a
blinded investigator. Commercially available CD-1 adult male mice
(~0.025 Kg body weight) were used for all studies and acclimatized
in home cages for 1 week prior to experimentation with ad libitum
access to food and water and on a 12 h light-dark cycle [23]. Routes
of drug administration, surgical protocols and data analysis are
detailed below. A total of 180 mice were used, complying with the
permitted animal usage outlined in the corresponding Home Ofﬁce
licence. The severity of all procedures was classiﬁed as mild.
2.3.1. Haemodynamic measurement of the hypotensive effect of
GSNO and SNOPCs in whole animal models
In vivo blood pressure was monitored in anaesthetized animals
as previously described [24]. A total of 12 wild type male mice were
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saline) control, GSNO, SNOPC-2 and SNOPC-6 treatments, respec-
tively. Mean arterial pressure was recorded in anaesthetized mice
(2% isoﬂurane in air) on a homeothermically controlled heating
blanket (Harvard Instruments, Edenbridge, UK). A 1.2F microtip
pressure catheter (Scisense, Transonic Systems, Ithaca, NY, USA)
was inserted into the right carotid artery and basal arterial pressure
was recorded for 5 min. Test drug solutions (50 mL containing
500 mmol/L NO z 1 mmol NO/kg body weight) or control (saline)
solution were directly injected into the jugular vein using a 30
gauge needle inserted through the underlying muscle. Arterial
blood pressure was recorded continuously for a further 5 min
following drug administration using a PowerLab data acquisition
system and Chart 7 software (ADInstuments, Oxford, UK).
2.3.2. Biodistribution studies after i.v. administration
A total of 72 mice were used (n¼ 3/time point/group) where the
groups represented the vehicle (0.9%saline) control, GSNO, SNOPC-
2 and SNOPC-6 treatments, respectively. A time course study (0,1, 3,
5,10 and 15min) was carried out to characterize the biodistribution
of NO metabolites (total NOx and nitrite) or labelled peptides in
different organs after i.v. injection. I.V. injection of a single volume
(50 mL) of test solution in saline (containing 500 mmol/L
NOz 1 mmol NO/kg body weight) or control (saline) solution was
given into the lateral tail vein of the mice while under anaesthesia
(2% isoﬂuorane). At the appropriate time point, animals were
exsanguinated by terminal bleed under anaesthesia (2% iso-
ﬂuorane). Blood samples were collected in heparinized tubes
(100 U/mL) and centrifuged at 1200 g for 5 min at 4 C to separate
the plasma from the cellular fraction.Without perfusing the organs,
the heart, liver and lung were dissected within 5 min and snap
frozen in liquid nitrogen and stored at 80 C until required for
further processing.
2.3.3. Biodistribution studies after i.n. administration
A total of 48micewere used (n¼ 3/group/time point) where the
groups represented vehicle (0.9%saline) control, GSNO, SNOPC-2
and SNOPC-6 treatments (n ¼ 3 per group), respectively. A time
course study (0, 1, 5 and 15 min) was carried out to characterize the
NOx biodistribution after i.n. administration of compounds. Prior to
drug administration, mice were anaesthetized by inhaling 2% iso-
ﬂurane in air via a nose cone. A single volume (20 mL) of test so-
lution in saline (containing 1.25 mmol/L NOz 1 mmol NO/kg body
weight) or control (saline) solution was then administered drop
wise into the nasal cavity using a micropipette after removing the
mouse momentarily from the anaesthetic mask cone and holding it
in an upright position. At the appropriate time point animals were
exsanguinated by terminal bleed under anaesthesia. Blood and
organ samples were collected and processed as described in section
2.4.
2.3.4. Quantiﬁcation of ﬂuorescently labelled PC oligopeptides
The fate of the PC oligopeptide backbone was assessed by direct
quantiﬁcation of 7-methoxycoumarin present in 100 mL plasma or
tissue homogenate collected at speciﬁed time points (0, 1, 5 and
15 min) post injecting animals in vivo with 7-methoxycoumarin
labelled drugs (n ¼ 3/group/time point, total of 48 mice). The
ﬂuorescence in plasma or tissue homogenate was measured at
lex ¼ 340 nm and lem ¼ 400 nm. Following subtraction of back-
ground ﬂuorescence from control tissues, the amount of
ﬂuorescent-labelled oligopeptide was calculated from a linear
calibration curve constructed from known concentration of 7-
methoxycoumarin-labelled compounds (linear range:
0.1e1.5 mmol *GSNO, *SNOPC-2 and *SNOPC-6, respectively). Values
were normalized for total amount of protein (mg) and expressed aspercentage of the initial dose (% ID/mg protein). Note: Because
compounds were dosed at equimolar NO concentrations, admin-
istered doses of the labelled PCs were: *GSNO: 1.00 mmol/kg,
*SNOPC-2: 0.50 mmol/kg, *SNOPC-6: 0.17 mmol/kg.2.4. Quantiﬁcation of total NOx and S-nitrosothiols
Prior to quantiﬁcation, tissue samples were thawed, weighed
and homogenized at 100mg tissue/mL in phosphate buffered saline
(PBS; pH 7.4) using a Silversonmodel L4RT laboratory homogenizer.
Homogenates were centrifuged at 13,000 g for 20 min at 4 C to
remove tissue debris. Whole blood samples were fractionated into
plasma (serum þ platelets) and blood cells (red and white blood
cells) by centrifugation at 1200 g. Cellular blood components were
lysed with lysis buffer (5 mmol/L Na o-vanadate, 10 mg/mL ben-
zamidine, 1 mmol/L phenylmethylsulfonyl ﬂuoride (PMSF),
10 mmol/L Tris HCl, 5 mmol/L ethylenediamine tetraacetic acid
(EDTA), 50 mmol/L NaCl pH 7.4 and 3.5 mmol/L SDS) at a volume
ratio of 1:5 cells: lysis buffer. These samples were centrifuged at
13,000 g for 20 min at 4 C. Protein content of each sample was
quantiﬁed using the Bradford assay [25].
Quantiﬁcation of total NOx was performed according to a
method described by Verdon et al. [26]. Brieﬂy, samples were de-
proteinated by mixing the sample with 0.3 mol/L NaOH and
aqueous 0.27 mol/L ZnSO4 at a volume ratio of 1:1:2. NOx was
determined in 50 mL de-proteinated sample in the form of nitrite
using the colorimetric Griess method [27,28]. The amount of nitrite
in each sample was calculated from a linear calibration curve of
known nitrite concentrations (linear range: 1e100 mmol/L) and
normalized for total amount of protein (mg), quantiﬁed using the
Bradford assay. The ﬁnal concentration, expressed as mMnitrite/mg
protein, represents the total NOx in the system. Any remaining
nitrite in the infusate (drug solution administered) was not
measured as we were more interested in in vivo changes in NOx
levels in untreated versus different treated groups at different time
points measured but we have previously characterized this [20].
Total S-nitrosothiol compounds (RSNO) were quantiﬁed in
plasma and the blood cell fraction only by gas-phase chem-
iluminescence reaction with ozone [29,30]. Brieﬂy, blood samples
were treated with 5 mmol/L N-ethylmaleimide (NEM) shortly after
withdrawal from mice to chelate copper and prevent RSNO
degradation. 300 mL of the test sample was quickly injected into a
purge vessel containing 2 mL potassium iodide solution (50 mg/
mL) and 6 mL glacial acetic acid under an NO-free N2 atmosphere.
The tri-iodide solution formed reduced RSNOs to NO gas which was
detected by using Eco Physics NO analyzer (model CLD88). Plasma
and blood cell RSNOs were quantiﬁed by the NO signal peak area of
the samples. Data were quantiﬁed using NOanalyser software.2.5. Data analysis
As each time point required a terminal bleed for blood and tis-
sue harvest, n ¼ 3 was the minimum number of animals to be used
to report that PK proﬁle over time whilst still complying with the
appropriate animal usage as outlined within the UK Home Ofﬁce
animal licence used for this body of work. All data were analyzed
using Graph Pad Prism 4 software. One-way or two-way analysis of
variance (ANOVA) followed by Bonferroni’s multiple comparison
post-test was used. The following systemwas used to denote the p-
value: *p < 0.05, **p < 0.01, ***p < 0.001.
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3.1. SNOPC-6 is more potent than SNOPC-2 and GSNO at equivalent
administered doses of NO
Intra venous administration of GSNO and SNOPCs at doses that
contained 1 mmol NO/kg body weight resulted in a rapid and
transient drop in blood pressure compared to the vehicle control.
Fig. 2A depicts a representative example of the haemodynamic
traces measured for each compound treatment and Fig. 2B depicts
the mean reduction in blood pressure and recovery for each
treatment group.What is striking about this data is the signiﬁcantlyFig. 2. Haemodynamic measurement of hypotensive effects of GSNO, SNOPC-2 and SNOPC
trace of mean arterial pressure measured over 5 min post-administration. (B) Mean arteri
compounds and the vehicle control. The table includes values of the maximum response
signiﬁcance levels. The data shown represent the mean ± SD of n ¼ 3 animals per group (greater reduction in blood pressure achieved by treatment with
SNOPC-6, despite administration of equivalent doses of NO for all
three compounds. This observation contrasts with results from an
in vitro study of vasodilation in isolated rat aortic rings, where the
dose-response curves of SNOPCs and GSNO were nearly identical
after treatment with equimolar concentrations of NO [19].
The discrepancy between the in vitro and in vivo performance of
the SNOPCs with regard to vasodilation may be in part explained by
the differences in stability of each compound in different envi-
ronments. In vitro, SNOPC decomposition rates (i.e. cleavage of
SeNO bonds and ‘release’ of NO from the compound) were found to
be compound-dependent with a rank order of: SNOPC-6 > SNOPC--6 after i.v. administration of compounds at equivalent NO doses. (A) A representative
al blood pressure expressed as percentage of pre-administration baseline for all three
achieved (%), time at which the maximum response occurred (tmax; s) and statistical
*p < 0.05, **p < 0.01, ***p < 0.001).
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solutions) is primarily driven by photo degradation or transition
metal-induced homo- and heterolytic cleavage of the covalent SNO
bond [31,32]. The addition of reducing agents, such as ascorbic acid,
may also stimulate decomposition, as well as the presence of other
thiols [31,33]. Transnitrosation, the transfer of NO from a donor
RSNO to an acceptor thiol without the release of gaseous NO, also
plays a large role in RSNO decomposition and is postulated to be the
primary mechanism of RSNO decomposition in vivo. This is because
other mechanisms, such as photodegradation, rarely occur in vivo
and transition metals are usually sequestered [31,32,34].
Of particular relevance to our in vivo observations, is a study by
Jourd’heuil et al. [34], who investigated the fate of GSNO and S-
nitrosated cysteine (CySNO) in human blood serum and whole
blood ex vivo. They observed that exogenously administered GSNO
and CySNO (10 mmol/L) fully decomposed in both plasma and
whole blood within 15 min, whereby ~85% decomposition took
place within in the ﬁrst 5 min. Half-lives of GSNO and CySNO were
~120 and 50 s, respectively. Inclusion of transition metal chelators
and inhibitors of xanthine oxidase, glutathione peroxidise and g-
glutamyl transpeptidase did not inﬂuence the decomposition rate,
implying that enzymatic or transition metal-induced pathways of
decomposition were not involved. However, amounts of S-nitroso
albumin (AlbSNO) increased by approximately 50e70%, providing
evidence that (under the conditions tested) transnitrosation from
low molecular weight RSNOs to AlbSNO was a primary mechanism
of low molecular weight RSNO decomposition in the blood.
Another study by Liu et al., also showed that the in vivo systemic
haemodynamic and in vitro vasodilation effects of low molecular
weight RSNOs such as GSNO or S-nitroso cysteine occur after
equilibration of the NO moiety amongst the plasma thiols (albu-
min) via S-transnitrosylation. This effect was persistent over time
where GSNO and S-nitroso cysteine showed a half-life of about
5 min [35].
Previous in vitro studies demonstrated that SNOPCs were more
potent transnitrosating agents compared to GSNO [20]. It may be
postulated that immediately following i.v. injection, all compounds
decomposed via transnitrosation reactions with serum albumin to
form AlbSNO or other RSNO, providing a circulating storage form of
bioactive NO, with SNOPC-6 decomposition occurring most rapidly,
followed by SNOPC-2 and GSNO. To test this hypothesis, the RSNO
content of fractionated blood (plasma vs. blood cells) was investi-
gated. Supporting the observation that RSNO, (including AlbSNO),
are an important storage form of NO in blood, a mean baseline
value of 0.2 ± 0.05 mmol/L was detected in the plasma compartment
(Fig. 3A; in line with literature values for baseline plasma RSNO
levels [36,37]). In comparison, the amount of RSNO in the cellular
fraction of blood was nearly undetectable under baseline condi-
tions (Fig. 3B). After treatment with both SNOPCs, a rapid increase
in total plasma RSNO was detected, which peaked at t ¼ 1 min and
rapidly returned to near baseline levels by t ¼ 5 min (Fig. 3A).
Contrary to the stated hypothesis, plasma RSNO levels were not
signiﬁcantly higher after SNOPC-6 treatment compared to those
observed following SNOPC-2 treatment. Thus, compound-
dependent transnitrosation rates may not alone be sufﬁcient to
explain the signiﬁcant differences in haemodynamic activity be-
tween the two SNOPC species. Interestingly, a concurrent elevation
in the RSNO levels in the cellular fraction of blood after SNOPC
treatment was observed, indicating the dynamic nature of trans-
nitrosation in the in vivo environment. The RSNO proﬁles in plasma
and the cellular compartment after GSNO administration provide
some evidence of a trend that GSNOmay bemore stable than either
of the SNOPCs and therefore participates in transnitrosation re-
actions at a slower rate compared to the SNOPCs (Fig. 3A and B);
however it should be noted that the NOx curves in plasmawere notsigniﬁcantly different from both SNOPC treatment groups (Fig. 4A).
Intravenous bolus injection of AlbSNO (0.001e0.3 mmol/kg) has
previously been shown to cause rapid and transient decreases in
blood pressure (~35% reduction compared to baseline) and its ac-
tivity potentiated by the co-administration of low molecular
weight thiols (~60% reduction) [38e40]. Thus, a rapid interaction
between GSNO/SNOPCs with serum albumin leading to trans-
nitrosation seems a likely intermediary process in the pharmaco-
logical activity of these compounds. The exact pathways by which
circulating RSNO release or transfer their NO cargo so that the NO
or NO metabolite can activate smooth muscle soluble guanylate
cyclase (sGC) leading subsequently to vasodilation, remains un-
known [34,41].
3.2. I.V. and I.N. administration of GSNO and SNOPCs elevates NOx
levels in selected tissues
The quantity and biodistribution of NO metabolites following
NO donor administration is often used to evaluate the overall
release of NO, as well as assess any targeting effect a delivery sys-
temmight have [38e40]. One basic approach is tomeasure the total
levels of NOx in the blood or tissue, which has the advantage of
encompassing a wide variety of NO metabolism pathways, most of
which ultimately result in formation of nitrites or nitrates. Total
levels of NOx were quantiﬁed in the heart, liver, lungs, blood
plasma and blood cellular fraction after administration of GSNO,
SNOPCs, or the vehicle control. Fig. 4A shows total NOx at 1, 3, 5, 10
and 15 min post-i.v. administration in selected organs where NOx
levels are signiﬁcantly increased compared to baseline. Baseline
(physiological) levels of NOx were measured to be ~10 mM nitrite/
mg protein for all organs tested (including those not depicted in
Fig. 4). I.V. administration of GSNO, SNOPC-2 and SNOPC-6 led to
signiﬁcantly elevated NOx levels in the plasma, lung, heart and
liver. At t ¼ 1 min total NOx in the lung was found to be elevated
3.1-, 3.4-, and 4.5-fold higher than the vehicle control group for
SNOPC-6, SNOPC-2 and GSNO, respectively. In the other compart-
ments, total NOx concentrations reached a maximum concentra-
tion at t ¼ 3 min and returned to near baseline levels by t ¼ 15 min.
GSNO-treated animals generally exhibited higher mean AUC values
in all compartments compared to other groups (Fig. 4C). It should
be noted that the 7-methoxycoumarin ﬂuorescent tag had no sig-
niﬁcant inﬂuence on the NOx biodistribution patterns for all com-
pounds tested (Figure A, supplementary data).
One of the most interesting attributes of SNOPCs as NO delivery
systems is the ability to generate a series of compounds with both
an increasing number of SNO moieties and controlled increases in
molecular weight. This allows a systematic investigation of the
impact of oligopeptide size and sequence on the pharmacodynamic
and pharmacokinetic proﬁles of the system using a variety of
different administration routes. Because pulmonary delivery of NO
donor compounds may be of some interest in diseases such as
pulmonary hypertension [21,22], the biodistribution of NOx was
investigated after i.n. administration of GSNO, SNOPC-2 and
SNOPC-6 (Fig. 4B). As hypothesized, it was observed that NOx levels
and mean AUC values were elevated in the lung tissue compared to
i.v. administration over a 15 min period. However, contrary to the
original hypothesis, administration of the high molecular weight
SNOPC-6 did not result in signiﬁcant retention of biologically active
NO in the lung compared to SNOPC-2 or GSNO. Again, this is likely
to be due to the rapid decomposition of SNOPC-6 and trans-
nitrosation reactions occurring in the lung. I.n. delivery of GSNO
and the SNOPCs resulted in a mild elevation of NOx in the blood
plasma, a moderate increase in liver levels and mild increases in
heart levels of NOx indicating that NO metabolites were trans-
ported across the respiratory epithelium into the blood or the
Fig. 3. (A) RSNO concentration proﬁle in blood plasma at t ¼ 0e15 min post i.v. administration of GSNO, SNOPC-2, SNOPC-6 (at equivalent molar concentrations of NO) and the
vehicle control. (B) RSNO concentration proﬁle in blood cell fraction at t ¼ 0e15 min post i.v. administration of GSNO, SNOPC-2, SNOPC-6 (at equivalent molar concentrations of NO)
and the vehicle control. The data shown represent the mean ± SD of n ¼ 3 animals per group per time point (*p < 0.05, **p < 0.01).
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epithelium and enter the blood stream, decomposing to release
their NO cargo once there and returning to baseline within 15 min.
Interesting comparisons may be made between the data
generated in this study and other similar systems. For example,
Katsumi et al. [38,39] investigated the pharmacodynamics and
pharmacokinetics of AlbSNO and pegylated AlbSNO after i.v.
administration of 1.5 mmol NO/kg, using GSNO as a control and
observed similar results for their GSNO and baselinemeasurements
as seen in this study. They showed that AlbSNO decomposed in vivo
at a much slower rate than GSNO and SNOPCs as indicated by its
higher tmax (~10 min) value for plasma nitrites. Interestingly,
pegylation of AlbSNO reduced SNO decomposition in vivo achieving
a signiﬁcantly greater AUC for plasma nitrite [30]. It has been
demonstrated that ‘caging’ of RSNO in polymer matrices is an
effective strategy to stabilize SNO moieties against in vivo decom-
position. In addition to pegylation of proteins [40], poly ethylene
glycol (PEG) hydrogels [42,43] and interpolymer RSNO complexes
composed of poly(vinyl methyl ether co-maleic anhydride)-poly
(vinyl pyrrolidone) [8] have been shown to slow RSNO decompo-
sition to achieve NO release over days. Cross linking SNO with
alginate was also found to sustain NO release from S-nitrosthiols.
Two compounds were synthesized with NO loading 174 ± 21 mmol/
g and 468 ± 23 mmol/g respectively. An ex vivo permeation study
showed that these compounds can exhibit a sustained release for at
least 10 h [44] Encapsulation of RSNO in polymeric nanoparticles
also provides a promising strategy in sustaining NO release from
RSNO. Eudragit® RL was used to prepare GSNO-loaded nano-
particles (GSNO-NP). Their release kinetics showed that Cmax was
reached within 3 h and remained stable till 6 h. In another study,
hollow S-nitrosothiol polymer nanoparticles as scaffolds for NO
release were prepared were the release of NO was controlled by
changing the polymer ratio and composition to reach a half-life
reaching 225 min [45,46]. Thus, a viable approach to tuning
SNOPC decomposition in vivo may be to conjugate the compounds
with a suitable polymeric system.3.3. Biodistribution of PC oligopeptides following i.v. administration
In addition to monitoring NOx biodistribution following NO
release, it was also of interest to track the fate of the PC oligopep-
tides after i.v. administration. To evaluate this, GSH, PC-2 and PC-6were purchased with a 7-methoxycoumarin tag attached to the N-
terminus of the peptide chain and nitrosylated according to the
same protocol as non-labelled peptides. Fig. 5 shows selected tis-
sues where levels of *GSNO, *SNOPC-2 and *SNOPC-6 associated
labels were quantiﬁed above the limit of detection at t ¼ 1, 3 and
5 min post-administration of compounds. A molecular weight-
dependent biodistribution pattern was observed for these com-
pounds, with overall tissue accumulation increasing as the molec-
ular weight of the peptide increased. The larger oligopeptides
showed an increased residence time in the plasma which depleted
over time as tissue distribution occurred. Higher concentrations
were detected in liver compared with other tissues studied. A
further interesting observation was the steady accumulation of
SNOPCs in the brain. As the animals were not perfused prior to
biodistribution studies, it would be interesting to investigate
whether PCs can cross the blood-brain barrier or simply accumu-
lated in the vasculature of the brain. If they are able to cross the
blood brain barrier, PCs may be a useful delivery system for other
types of compounds in addition to NO, which require blood-brain
barrier transport systems.
Little information is available on the susceptibility of PCs to
enzymatic degradation, especially by mammalian proteases and
peptidases. If analogous to GSH catabolism, PC degradation will
likely occur via the g-glutamyl cycle [47]. Thus, exogenously
administered PCs may be a substrate of the cell surface enzyme, g-
glutamyl transpeptidase (GGT), which is the initial step in the
metabolism of plasma GSH. In humans, GGT is expressed fairly
widely, although the highest activity is found in the proximal tu-
bules of the kidneys [47]. GGT activity controls levels of plasma GSH
and keeps them at the relatively low concentration of ~4 mmol/L
[48]. A comparison of the biodistribution data for *GSNO and the
*SNOPCs provides some limited, indirect evidence that PC distri-
bution and metabolism may differ from GSH. Despite a two to six-
fold higher administered dose of GSNO compared to the SNOPCs,
*GSNO/*GSH recovery from blood and tissues was generally very
low, indicating a rapid and widespread distribution in addition to
metabolism by the GGT pathway. Despite the lower administration
dose, *SNOPCs/*PCs were recovered at much higher concentrations
in blood and tissues, whichmay indicate that they remain intact for
signiﬁcantly longer periods of time compared to GSH and therefore
exhibit a very different tissue accumulation proﬁle. This informa-
tion is of interest, because very few studies in the literature report
Fig. 4. (A) Biodistribution of NOx in selected tissues at t ¼ 0e15 min post i.v. administration of GSNO, SNOPC-2, SNOPC-6 (1 mmol NO/kg) and the vehicle control. (B) Biodistribution
of NOx in selected tissues at t ¼ 0e15 min post i.n. administration of GSNO, SNOPC-2, SNOPC-6 (1 mmol NO/kg) and the vehicle control. Data points represent the mean ± SD of n ¼ 3
animals per group per time point (*p < 0.05, **p < 0.01, ***p < 0.001). (C) Pharmacokinetic analysis of NOx in each compartment including comparison of the two administration
routes.
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Fig. 5. Biodistribution of 7-methoxycoumarin-labelled PCs and GSNO at t ¼ 1e5 min
post administration of *GSNO (A), *SNOPC-2 (B), *SNOPC-6 (C). The data shown
represent the mean ± SD of n ¼ 3 animals per time point per group (*p < 0.05,
**p < 0.01, ***p < 0.001).
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peptides such as those containing the integrin-binding RGDsequence [49,50]). In this respect, PCs may also serve as useful tools
for applications beyond NO delivery. For example, it would be
interesting to utilise the chelating properties of PCs to bind radio-
metals for nuclear imaging, which would allow for greater sensi-
tivity and accuracy in biodistribution studies.
4. Conclusions
This study investigated the haemodynamic effects of SNOPCs
compared with GSNO after i.v. administration and demonstrated
that larger SNOPCs such as SNOPC-6 elicit a potent, but transient
reduction in blood pressure. The mechanism of this potent effect
was hypothesized to result from the excellent transnitrosating
properties of SNOPCs. All compounds tested in this study exhibited
a corresponding spike of NOx in plasma and selected tissues after
both i.v. and i.n. administration although no signiﬁcant differences
in NOx patterns were observed between the compounds. Of
particular interest in this study was the observation of selective
accumulation of the PC oligopeptides in several organs, notably the
brain. Apart from cell targeting peptide sequences, such as RGD,
little data exists on the biodistribution patterns of therapeutic oli-
gopeptides with different molecular weights.
Overall, the clinical relevance of this study data lies in a greater
understanding of the fundamental SNO chemistry, which will in-
ﬂuence RSNO decomposition in vivo and lead to compound design
with variable NO release properties and thus greater control over
pharmacological activity. The study demonstrates that SNOPCs can
produce a more potent haemodynamic effect compared to GSNO
resulting from changes to the compound structure, i.e. increase in
molecular weight and modulation in the stability of SNO groups. It
would be feasible that continuous i.v. administration of SNOPCs
may be therapeutically valuable in clinical scenarios where a potent
vasodilatory effect is required. Additionally, combination of SNOPCs
with other drug delivery strategies, such as polymer conjugation,
may also allow for modulation of NO release to suit a desired
pharmacokinetic proﬁle. Finally, this study also provides inter-
esting general information on non-targeted oligopeptide bio-
distribution and may be a stimulus to investigate the usefulness of
PCs as drug carriers or chelators for radiometals in a wider range of
applications.
Acknowledgements
This work was supported by the Maplethorpe Fund and the
British Heart Foundation.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.niox.2016.06.006.
References
[1] R.O. Cannon, Role of nitric oxide in cardiovascular disease: focus on the
endothelium (vol 44, pg 1809, 1998), Clin. Chem. 44 (9) (1998) 2070, 2070.
[2] C. Napoli, L.J. Ignarro, Nitric oxide and pathogenic mechanisms involved in the
development of vascular diseases, Arch. Pharmacal Res. 32 (8) (2009)
1103e1108.
[3] H. Katsumi, M. Nishikawa, M. Hashida, Development of nitric oxide donors for
the treatment of cardiovascular diseases, Cardiovasc. Hematol. Agents Med.
Chem. 5 (3) (2007) 204e208.
[4] H. Katsumi, et al., Prevention of hepatic ischemia/reperfusion injury by pro-
longed delivery of nitric oxide to the circulating blood in mice, Trans-
plantation 85 (2) (2008) 264e269.
[5] G. Han, et al., Nitric oxide releasing nanoparticles are therapeutic for Staph-
ylococcus aureus abscesses in a murine model of infection, PloS One 4 (11)
(2009).
[6] S. Huerta, S. Chilka, B. Bonavida, Nitric oxide donors: novel cancer
L. Heikal et al. / Nitric Oxide 59 (2016) 1e9 9therapeutics (Review), Int. J. Oncol. 33 (5) (2008) 909e927.
[7] S.J. Wimalawansa, Rationale for using nitric oxide donor therapy for preven-
tion of bone loss and treatment of osteoporosis in humans, in: M. Zaidi (Ed.),
Skeletal Biology and Medicine, Pt B: Disease Mechanisms and Therapeutic
Challenges, 2007, pp. 283e297.
[8] Y. Li, P.I. Lee, Controlled nitric oxide delivery platform based on S-Nitrosothiol
conjugated interpolymer complexes for diabetic wound healing, Mol. Pharm.
7 (1) (2010) 254e266.
[9] J. Saraiva, et al., Nanocarriers for nitric oxide delivery, J. drug Deliv. 2011
(2011) 936438, 936438.
[10] F. Dahboul, et al., S, S ’-dinitrosobucillamine, a new nitric oxide donor, induces
a better vasorelaxation than other S-nitrosothiols, Eur. J. Pharmacol. 730
(2014) 171e179.
[11] H.H. Al-Sa’doni, A. Ferro, S-nitrosothiols as nitric oxide-donors: chemistry,
biology and possible future therapeutic applications, Curr. Med. Chem. 11 (20)
(2004) 2679e2690.
[12] L. Piras, et al., S-Nitroso-beta-Cyclodextrins as new bimodal carriers: prepa-
ration, detailed characterization, nitric-oxide release, and molecular encap-
sulation, Chem. an 8 (11) (2013) 2768e2778.
[13] Y. Ishima, et al., Poly-s-nitrosated albumin as a safe and effective multifunc-
tional antitumor agent: characterization, biochemistry and possible future
therapeutic applications, BioMed Res. Int. 2013 (2013) 353892, 353892.
[14] W.E. Rauser, Phytochelatins and related peptides- structure, biosynthesis, and
function, Plant Physiol. 109 (4) (1995) 1141e1149.
[15] C.S. Cobbett, Phytochelatins and their roles in heavy metal detoxiﬁcation,
Plant Physiol. 123 (3) (2000) 825e832.
[16] L. Elviri, et al., Identiﬁcation of in vivo nitrosylated phytochelatins in Arabi-
dopsis thaliana cells by liquid chromatography-direct electrospray-linear ion
trap-mass spectrometry, J. Chromatogr. A 1217 (25) (2010) 4120e4126.
[17] R. De Michele, et al., Nitric oxide is involved in cadmium-induced pro-
grammed cell death in arabidopsis suspension cultures, Plant Physiol. 150 (1)
(2009) 217e228.
[18] O. Lamotte, et al., Protein S-nitrosylation: speciﬁcity and identiﬁcation stra-
tegies in plants, Front. Chem. 2 (2014) 114, 114.
[19] L. Heikal, et al., S-Nitrosophytochelatins: investigation of the bioactivity of an
oligopeptide nitric oxide delivery system, Biomacromolecules 12 (6) (2011)
2103e2113.
[20] L. Heikal, G.P. Martin, L.A. Dailey, Characterisation of the decomposition
behaviour of S-nitrosoglutathione and a new class of analogues: S-Nitro-
sophytochelatins, Nitric Oxide-Biol. Chem. 20 (3) (2009) 157e165.
[21] B.R. Jacobs, et al., Aerosolized soluble nitric oxide donor improves oxygena-
tion and pulmonary hypertension in acute lung injury, Am. J. Respir. Crit. Care
Med. 158 (5) (1998) 1536e1542.
[22] K.C. Young, et al., The effect of a nebulized NO donor, DPTA/NO, on acute
hypoxic pulmonary hypertension in newborn piglets, Biol. Neonate 85 (3)
(2004) 195e202.
[23] C. Kilkenny, et al., ARRIVE Guidelines, 2010. Available from: https://www.
nc3rs.org.uk/arrive-guidelines.
[24] M. Nandi, et al., Genetic and pharmacological inhibition of dimethylarginine
dimethylaminohydrolase 1 is protective in endotoxic shock, Arterioscler.
Thromb. Vasc. Biol. 32 (11) (2012) 2589.
[25] C.M. Stoscheck, Quantitation of protein, Methods Enzym. 182 (1990) 50e68.
[26] C.P. Verdon, B.A. Burton, R.L. Prior, Sample pretreatment with nitrate reduc-
tase and glucose-6-phosphate-dehydrogenase quantitatively reduces nitrate
while avoiding interference by NADP(þ) when the Griess reaction is used to
assay for nitrite, Anal. Biochem. 224 (2) (1995) 502e508.[27] I. Guevara, et al., Determination of nitrite/nitrate in human biological material
by the simple Griess reaction, Clin. Chim. Acta 274 (2) (1998) 177e188.
[28] K.M. Miranda, M.G. Espey, D.A. Wink, A rapid, simple spectrophotometric
method for simultaneous detection of nitrate and nitrite, Nitric Oxide-Biol.
Chem. 5 (1) (2001) 62e71.
[29] X. Yang, et al., An improved mass spectrometry-based measurement of NO
metabolites in biological ﬂuids, Free Radic. Biol. Med. 56 (2013) 1e8.
[30] R. Marley, et al., A chemiluminescense-based assay for S-nitrosoalbumin and
other plasma S-nitrosothiols, Free Radic. Res. 32 (1) (2000) 1e9.
[31] N. Hogg, The biochemistry and physiology of S-nitrosothiols, Annu. Rev.
Pharmacol. Toxicol. 42 (2002) 585e600.
[32] K.A. Broniowska, N. Hogg, The chemical biology of S-Nitrosothiols, Antioxid.
Redox Signal. 17 (7) (2012) 969e980.
[33] Y. Lu, et al., S-Nitrosothiol-modiﬁed nitric oxide-releasing chitosan oligosac-
charides as antibacterial agents, Acta Biomater. 12 (2015) 62e69.
[34] D. Jourd’heuil, et al., Dynamic state of S-nitrosothiols in human plasma and
whole blood, Free Radic. Biol. Med. 28 (3) (2000) 409e417.
[35] T. Liu, et al., Local and systemic vasodilatory effects of lowmolecular weight S-
nitrosothiols, Free Radic. Biol. Med. 91 (2016) 215e223.
[36] U.B. Hendgen-Cotta, et al., Dietary nitrate supplementation improves revas-
cularization in chronic ischemia, Circulation 126 (16) (2012) 1983.
[37] R. Rossi, et al., Physiological levels of S-nitrosothiols in human plasma, Circ.
Res. 89 (12) (2001) E47. E47.
[38] H. Katsumi, et al., Development of polyethylene glycol-conjugated poly-S-
nitrosated serum albumin, a novel S-nitrosothiol for prolonged delivery of
nitric oxide in the blood circulation in vivo, J. Pharmacol. Exp. Ther. 314 (3)
(2005) 1117e1124.
[39] H. Katsumi, et al., Physicochemical, tissue distribution, and vasodilation
characteristics of nitrosated serum albumin: delivery of nitric oxide in vivo,
J. Pharm. Sci. 93 (9) (2004) 2343e2352.
[40] H. Katsumi, et al., Prevention of ischemia/reperfusion injury by hepatic tar-
geting of nitric oxide in mice, J. Control. Release 140 (1) (2009) 12e17.
[41] E. Nagababu, J.M. Rifkind, Routes for formation of S-Nitrosothiols in blood, Cell
Biochem. Biophys. 67 (2) (2013) 385e398.
[42] I. Hornyak, et al., Increased stability of S-nitrosothiol solutions via pH mod-
ulations, Free Radic. Res. 46 (2) (2012) 214e225.
[43] S.M. Shishido, M.G. de Oliveira, Polyethylene glycol matrix reduces the rates of
photochemical and thermal release of nitric oxide from S-nitroso-N-ace-
tylcysteine, Photochem. Photobiol. 71 (3) (2000) 273e280.
[44] S. Shah, et al., Synthesis of S-nitrosoglutathione-alginate for prolonged de-
livery of nitric oxide in intestines, Drug Deliv. 15 (2015) 1e9.
[45] W. Wu, et al., Time lasting S-nitrosoglutathione polymeric nanoparticles delay
cellular protein S-nitrosation, Eur. J. Pharm. Biopharm. 89 (2015) 1e8.
[46] T. Liu, et al., Hollow polymer nanoparticles with S-nitrosothiols as scaffolds for
nitric oxide release, J. Colloid Interface Sci. 459 (2015) 115e122.
[47] O.W. Grifﬁth, A. Meister, Glutathione-Interorgan translocation, turnover, and
metabolism, Proc. Natl. Acad. Sci. U. S. A. 76 (11) (1979) 5606e5610.
[48] F. Michelet, et al., Blood and plasma glutathione measured in healthy-subjects
by HPLC- Relation to sex, aging, biological variables, and life habits, Clin.
Chem. 41 (10) (1995) 1509e1517.
[49] M. Glaser, et al., Radiosynthesis and biodistribution of cyclic RGD peptides
conjugated with novel F-18 ﬂuorinated aldehyde-containing prosthetic
groups, Bioconjugate Chem. 19 (4) (2008) 951e957.
[50] E. Blom, et al., Ga-68-Labeling of RGD peptides and biodistribution, Int. J. Clin.
Exp. Med. 5 (2) (2012) 165e172.
